The immunoexpression of heparanase 2 in normal epithelium, intraepithelial, and invasive squamous neoplasia of the cervix

Journal of Lower Genital Tract Disease

Volumn 16, Issue 3, 2012, Pages 256-262

  Marques, Renato Moretti ^a,b   Focchi, Gustavo Rubino ^a   Theodoro, Thérèse Rachell ^c   Castelo, Adauto ^a   Pinhal, Maria Aparecida ^c   Nicolau, Sérgio Mancini ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF TAUBATÉ   (Brazil)

^c ABC   (Brazil)

Author keywords

cervical intraepithelial neoplasia; heparanase 2; immunohistochemistry; invasive squamous cell carcinoma

Indexed keywords

HEPARANASE; HEPARANASE 2; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; SEMIQUANTITATIVE METHOD; SQUAMOUS EPITHELIUM; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; AGED; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GLUCURONIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REFERENCE VALUES; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84863568220     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0b013e3182422c69     Document Type: Article

References (23)

1. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-86.
2. National Institute for the Fight Against Cancer (INCA). In Estimated Incidence and Mortality of Cancer in Brazil. xAvailable at: Http://www.inca.gov. br/estimativa/2008/index.asp?link=conteudo-view.asp&ID=5. Accessed December 24, 2010.
3. Schrö pfer A, Kammerer U, Kapp M, Dietl J, Feix S, Anacker J. Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. BMC Cancer 2010; 10 553
4. Roycik MD, Fang X, Sang QX. A fresh prospect of extracellular matrix hydrolytic enzymes and their substrates. Curr Pharm Des 2009;15:1295-308.
5. Vlodavsky I, Goldshmidt O. Properties and function of heparanase in cancer metastasis and angiogenesis. Haemostasis 2001;1:60-3.
6. Schubert SY, Ilan N, Shushy M, Ben-Izhak O, Vlodavsky I, Goldshmidt O. Human heparanase nuclear localization and enzymatic activity. Lab Invest 2004;84: 535-44.
7. Vlodavsky I, Elkin M, Abboud-Jarrous G, Levi-Adam F, Fuks L, Shafat I, et al. Heparanase: One molecule with multiple functions in cancer progression. Connect Tissue Res 2008; 49:207-10.
8. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I. Proteoglycans in health and disease: New concepts for heparanase function in tumor progression and metastasis. FEBS J 2010;277:3890-903.
9. Demir M, Iqbal O, Hoppensteadt DA, Piccolo P, Ahmad S, Schultz CL, et al. Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88). Clin Appl Thromb Hemost 2001; 7:131-40.
10. Levy-Adam F, Feld S, Cohen-Kaplan V, Shteingauz A, Gross M, Arvatz G, et al. Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem 2010;285:28010-9.
11. Vreys V, David G. Mammalian heparanase: What is the message? J Cell Mol Med 2007;11:427-52.
12. Peretti T, Waisberg J, Mader AM, de Matos LL, da Costa RB, Conceiçäo GM, et al. Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma. Eur J Gastroenterol Hepatol 2008;20:756-65.
13. Theodoro TR, de Matos LL, Sant Anna AV, Fonseca FL, Semedo P, Martins LC, et al. Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis. Neoplasia 2007;9:504-10.
14. de Moura JP Jr, Nicolau SM, Stávale JN, da Silva Pinhal MA, de Matos LL, Baracat EC, et al. Heparanase-2 expression in normal ovarian epithelium and in benign and malignant ovarian tumors. Int J Gynecol Cancer 2009;19: 1494-500.
15. Varchalama E, Rodolakis A, Strati A, Papageorgiou T, Valavanis C, Vorgias G, et al. Quantitative analysis of heparanase gene expression in normal cervical, cervical intraepithelial neoplastic, and cervical carcinoma tissues. Int J Gynecol Cancer 2009;19:1614-9.
16. Richart RM. Cervical intraepithelial neoplasia. Pathol Annu 1973;8:301-28.
17. Fonseca FL, Sant Ana AV, Bendit I, Arias V, Costa LJ, Pinhal AA, et al. Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients. Breast Cancer Res 2005;7:R28-32.
18. Matos LL, Stabenow E, Tavares MR, Ferraz AR, Capelozzi VL, Pinhal MA. Immunohistochemistry quantification by digital computer-Assisted method compared to semiquantitative analysis. Clinics 2006;61:417-24.
19. Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001;61:4655-9.
20. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Bü chler MW, Lander AD, et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 1998;102:1662-73.
21. Xu X, Ding J, Rao G, Shen J, Prinz RA, Rana N, et al. Estradiol induces heparanase-1 expression and heparin sulphate proteoglycan degradation in human endometrium. Hum Reprod 2007;22:927-37.
22. Bar-Sela G, Kaplan-Cohen V, Ilan N, Vlodavsky I, Ben-Izhak O. Heparanase expression in nasopharyngeal carcinoma inversely correlates with patient survival. Histopathology 2006; 49:188-93.
23. Doweck I.Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N, Vlodavsky I. Heparanase localization and expression by head and neck cancer: Correlation with tumor progression and patient survival. Neoplasia 2006;8:1055-61.